肝癌中的信号通路:病原和向治疗
Yangtao Xue1,2,3,4,5, Yeling Ruan1,2,3,4,5, Yali Wang1,2,3,4,5
1Key Laboratory of Laparoscopic Technology of Zhejiang Province, Department of General Surgery, Sir Run-Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, 310016, China.
肝癌向治疗,包括氨酸激酶抑制剂 (TKIs),显示出希望,但面临药物耐药性. 创新策略对于改善晚期肝癌患者的治疗结果至关重要.
科学领域:
- 肝病学和瘤学 肝病学和瘤学
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 肝癌,特别是肝细胞癌 (HCC),在全球的发病率和死亡率很高.
- 晚期诊断往往排除了手术选择,需要有效的全身治疗.
- 氨酸激酶抑制剂 (TKIs) 是晚期肝癌的主要向治疗方法,但耐药性限制了疗效.
研究的目的:
- 审查肝癌发病过程中的信号通路.
- 讨论针对这些途径的当前和研究中的抑制剂.
- 专注于TKIs和HCC的抵抗机制.
主要方法:
- 关于肝癌中信号通路的深入文献综述.
- 对这些途径在HCC中的致癌作用的分析.
- 检查TKI机制和抵抗现象.
主要成果:
- 确定了与肝癌有关的关键信号通路.
- 详细介绍了这些途径在HCC发育中的作用.
- 在HCC治疗中阐明了TKI耐药性的机制.
结论:
- 针对性疗法,特别是TKI,对于晚期肝癌至关重要.
- 对TKI的耐药性是一个重大的临床挑战.
- 开发新的有针对性的策略是克服局限性和改善患者预后的必要条件.
更多相关视频
00:06An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
09:03Establishment of Hepatocarcinoma in BALB/c-nu Mice and Investigation of the Therapeutic Effect of the Sanleng Jiashen Formula
Published on: January 26, 2024
相关概念视频
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Non-Canonical Wnt Signaling Pathways
Canonical Wnt Signaling Pathway
Liver Regeneration
Cells of Liver
The liver comprises four major types of cells— hepatocytes, stellate, Kupffer, and sinusoidal endothelial cells. The hepatocytes are...
PI3K/mTOR/AKT Signaling Pathway
